Symptomatic Vitreomacular Adhesion (VMA) (DBCOND0071467)
Identifiers
- Synonyms
- Symptomatic Vitreomacular Adhesion
Associated Data
- Indicated Drugs and Targets
Drug Description Targets Ocriplasmin A proteolytic enzyme used to treat symptomatic vitreomacular adhesion by dissolving the protein matrix responsible for the adhesion between the vitreous and macula.- Alpha-2-macroglobulintarget
- Alpha-2-antiplasmintarget
- Fibronectintarget
- Clinical Trials
Identifier Title Drug(s) Purpose Phase Status NCT02193945 A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA No drug interventions Not Available Not Available completed NCT01889251 A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion treatment 3 completed NCT01287988 Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies Not Available Not Available completed NCT02079883 Ocriplasmin Research to Better Inform Treatment (ORBIT) No drug interventions Not Available Not Available completed